Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01335074
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Temsirolimus + Sorafenib
Sponsor
Philipps University Marburg